00:51:07 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Hansa Biopharma är verksamma inom bioteknik. Bolaget är specialiserade inom forskning och utveckling av immunmodulerande enzymer. Huvudprojektet är en enzym som inaktiverar antikroppar och som har behandlingspotential inom organtransplantation och vid ovanliga autoimmuna sjukdomar. Övriga projekt fokuserar på utveckling av nya antikroppsmodulerande enzymer samt HBP-analys.

Kalender

2021-10-21 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-14 Ordinarie utdelning HNSA 0.00 SEK
2021-05-12 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-02-04 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-06-24 Ordinarie utdelning HNSA 0.00 SEK
2020-06-23 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-02-06 Bokslutskommuniké 2019
2019-10-31 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning HNSA 0.00 SEK
2019-05-22 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-08 Bokslutskommuniké 2018
2018-11-01 Kvartalsrapport 2018-Q3
2018-07-19 Kvartalsrapport 2018-Q2
2018-05-30 Ordinarie utdelning HNSA 0.00 SEK
2018-05-29 Årsstämma 2018
2018-04-25 Kvartalsrapport 2018-Q1
2018-02-14 Bokslutskommuniké 2017
2017-12-22 Extra Bolagsstämma 2017
2017-11-14 Kvartalsrapport 2017-Q3
2017-07-20 Kvartalsrapport 2017-Q2
2017-05-24 Ordinarie utdelning HNSA 0.00 SEK
2017-05-23 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-11-21 Extra Bolagsstämma 2016
2016-11-09 Kvartalsrapport 2016-Q3
2016-07-21 Kvartalsrapport 2016-Q2
2016-05-11 Årsstämma 2016
2016-04-28 Ordinarie utdelning HNSA 0.00 SEK
2016-04-27 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-10-28 Kvartalsrapport 2015-Q3
2015-08-25 Kvartalsrapport 2015-Q2
2015-04-17 Ordinarie utdelning HNSA 0.00 SEK
2015-04-16 Årsstämma 2015
2015-04-16 Kvartalsrapport 2015-Q1
2015-02-05 Bokslutskommuniké 2014
2014-07-25 Kvartalsrapport 2014-Q2
2014-06-04 Ordinarie utdelning HNSA 0.00 SEK
2014-06-03 Årsstämma 2014
2014-03-05 Extra Bolagsstämma 2014
2014-02-05 Bokslutskommuniké 2013
2013-07-25 Kvartalsrapport 2013-Q2
2013-05-07 Ordinarie utdelning HNSA 0.00 SEK
2013-05-06 Årsstämma 2013
2013-02-07 Bokslutskommuniké 2012
2012-09-28 Kapitalmarknadsdag 2012
2012-07-26 Kvartalsrapport 2012-Q2
2012-05-14 Årsstämma 2012
2012-02-09 Bokslutskommuniké 2011
2012-01-09 Extra Bolagsstämma 2011
2011-07-28 Kvartalsrapport 2011-Q2
2011-05-12 Årsstämma 2011
2011-05-06 Ordinarie utdelning HNSA 0.00 SEK
2010-04-30 Ordinarie utdelning HNSA 0.00 SEK
2010-02-10 Bokslutskommuniké 2009
2009-07-30 Kvartalsrapport 2009-Q1
2009-05-12 Kvartalsrapport 2009-Q2
2009-04-30 Ordinarie utdelning HNSA 0.00 SEK
2009-04-29 Årsstämma 1
2020-07-08 17:31:00

The capital injection will enable Hansa Biopharma to fund its R&D efforts, incl. advancing its three phase 2 programs and development of the next generation enzymes for repeat dosing. In addition the Company intends to fund the commercial build-up in Europe. 

NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR INTO ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THE SECURITIES REFERRED TO HEREIN, IN OR INTO ANY JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.

Lund, Sweden July 8, 2020. Hansa Biopharma, ("Hansa") the leader in immuno-modulatory enzyme technology for rare IgG mediated diseases, today announced its intention to issue up to approximately 4.4 million new ordinary shares through an accelerated bookbuild placing to institutional investors (the "Placing"). 

The Placing is being conducted through an accelerated book building process, which will commence immediately following this announcement and may close at any time. The offer price will be determined after the close of the accelerated book-building process. Once the Placing is completed the Board of Directors of Hansa Biopharma intends to resolve upon a directed share issue pursuant to the authorisation granted by the Annual General Meeting held on June 23, 2020.

A further announcement will be made following the completion of the Placing. In conjunction with the Placing, the Company has engaged Morgan Stanley & Co. International plc and Kempen & Co as joint bookrunners and Zonda Partners AB as co-manager, as well as Advokatfirman Vinge as legal adviser. White & Case acts as legal adviser to the banks in connection with the Placing.

The net proceeds of the Placing will be used to continue the development and expansion of the Company's R&D pipeline as well as to fund the potential launch and commercialization of imlifidase in kidney transplantation. More specifically, the proceeds will enable the Company to:
  • Fund the Company's ongoing and future R&D efforts, including development of imlifidase for additional indications such as antibody-mediated kidney transplant rejection (AMR), Guillain-Barré syndrome (GBS) and anti-GBM disease (GBM);
  • Fund Hansa Biopharma's ongoing commercial build-up, including expanding the sales force, in preparation for the potential launch of imlifidase in kidney transplantation in highly sensitized patients in Europe;
  • Continue to invest in the Company's development of next generation IgG-eliminating enzymes for repeat dosing; and
  • Fund working capital and general corporate purposes

The reasons for the deviation from the shareholders' pre-emption rights are to secure a capital raise in a timely and cost-efficient manner, as well as to strengthen the shareholder base of the Company.
Subject to customary exceptions, the Company and the management and board members of the Company have agreed to undertake a lock-up commitment for 90 calendar days following settlement of the Placing.

First half 2020- Key financials
Due to the contemplated directed issue Hansa Biopharma hereby chooses to provide an update on certain financial information for the period January 1 - June 30, 2020, with comparative figures for the corresponding period in 2019. The figures are preliminary and unaudited and have been retrieved from the Company's management accounts. The final figures are expected to be presented in the Company's interim report for the period ending June 30, 2020, which are scheduled to be published on July 16, 2020.

In MSEK; Unaudited, H1 2020 preliminary H1 2020 H1 2019
Operating profit / loss -193.2 -156.4
Cash flow from operating activities -198.6 -179.6
Cash and short-term investments (June 30) 400.2 762.7
 

IMPORTANT INFORMATION

THE RELEASE, ANNOUNCEMENT OR DISTRIBUTION OF THIS PRESS RELEASE MAY, IN CERTAIN JURISDICTIONS, BE SUBJECT TO RESTRICTIONS. THE RECIPIENTS OF THIS PRESS RELEASE IN JURISDICTIONS WHERE THIS PRESS RELEASE HAS BEEN PUBLISHED OR DISTRIBUTED SHALL INFORM THEMSELVES OF AND FOLLOW SUCH RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN HANSA BIOPHARMA IN ANY JURISDICTION, NEITHER FROM HANSA BIOPHARMA NOR FROM SOMEONE ELSE.
ANY INVESTMENT DECISION IN CONNECTION WITH THE PLACING MUST BE MADE ON THE BASIS OF ALL PUBLICLY AVAILABLE INFORMATION RELATING TO THE COMPANY AND THE COMPANY'S SHARES. SUCH INFORMATION HAS NOT BEEN INDEPENDENTLY VERIFIED BY MORGAN STANLEY & CO. INTERNATIONAL PLC, VAN LANSCHOT KEMPEN WEALTH MANAGEMENT NV OR ZONDA PARTNERS AB. THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO RELIANCE MAY BE PLACED FOR ANY PURPOSE ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT OR ITS ACCURACY OR COMPLETENESS.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE, OR FORM PART OF, AN OFFER TO SELL, OR A SOLICITATION OF AN OFFER TO PURCHASE ANY SECURITY IN THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES EXCEPT TO "QUALIFIED INSTITUTIONAL BUYERS" AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. ALL OFFERS AND SALES OF SECURITIES OUTSIDE OF THE UNITED STATES WILL BE MADE IN RELIANCE ON, AND IN COMPLIANCE WITH, REGULATION S UNDER THE SECURITIES ACT. THERE IS NO INTENTION TO MAKE A PUBLIC OFFERING OF THE SECURITIES IN THE UNITED STATES.
THE SECURITIES MAY NOT AND WILL NOT BE OFFERED OR SOLD IN CANADA, JAPAN OR AUSTRALIA.
WITH RESPECT TO THE MEMBER STATES OF THE EUROPEAN ECONOMIC AREA (EACH A "RELEVANT MEMBER STATE") AND THE UNITED KINGDOM SUBJECT TO REGULATION 2017/1129/EU (TOGETHER WITH ANY APPLICABLE IMPLEMENTING MEASURES, THE "PROSPECTUS REGULATION"), NO ACTION HAS BEEN UNDERTAKEN OR WILL BE UNDERTAKEN TO MAKE AN OFFER TO THE PUBLIC OF THE SECURITIES REFERRED TO HEREIN REQUIRING THE PUBLICATION OF A PROSPECTUS IN ANY RELEVANT MEMBER STATE OR IN THE UNITED KINGDOM. AS A RESULT, THESE SECURITIES MAY ONLY BE OFFERED OR SOLD IN ANY RELEVANT MEMBER STATE OR IN THE UNITED KINGDOM PURSUANT TO AN EXEMPTION UNDER THE PROSPECTUS REGULATION. 
THIS ANNOUNCEMENT IS ONLY ADDRESSED TO, AND DIRECTED AT, PERSONS IN RELEVANT MEMBER STATES OF THE EUROPEAN ECONOMIC AREA AND IN THE UNITED KINGDOM WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF ARTICLE 2(e) OF THE PROSPECTUS REGULATION ("QUALIFIED INVESTORS"). 
IN THE UNITED KINGDOM, THIS ANNOUNCEMENT IS DIRECTED ONLY AT, QUALIFIED INVESTORS (I) WHO ARE "INVESTMENT PROFESSIONALS" FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER"), OR (II) PERSONS FALLING WITHIN ARTICLE 49(2)(A)-(D) ("HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS ETC") OF THE ORDER ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS ("RELEVANT PERSONS"). UNDER NO CIRCUMSTANCES SHOULD PERSONS WHO ARE NOT RELEVANT PERSONS RELY OR ACT UPON THE CONTENTS OF THIS ANNOUNCEMENT. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IN THE UNITED KINGDOM IS AVAILABLE ONLY TO, AND WILL BE ENGAGED ONLY WITH, RELEVANT PERSONS.
IN SWEDEN, THIS PRESS RELEASE IS DIRECTED ONLY AT PERSONS WHO ARE QUALIFIED INVESTORS. 
MORGAN STANLEY & CO. INTERNATIONAL PLC, VAN LANSCHOT KEMPEN WEALTH MANAGEMENT NV AND ZONDA PARTNERS AB ARE ACTING FOR HANSA BIOPHARMA AND FOR NO ONE ELSE IN CONNECTION WITH THE TRANSACTION AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN HANSA BIOPHARMA FOR PROVIDING THE PROTECTIONS AFFORDED TO CUSTOMERS OF MORGAN STANLEY & CO. INTERNATIONAL PLC, VAN LANSCHOT KEMPEN WEALTH MANAGEMENT NV AND ZONDA PARTNERS AB OR FOR AFFORDING ADVICE IN RELATION TO THE TRANSACTION, THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO IN THIS ANNOUNCEMENT. EITHER OF THE MORGAN STANLEY & CO. INTERNATIONAL PLC, VAN LANSCHOT KEMPEN WEALTH MANAGEMENT NV AND ZONDA PARTNERS AB MAY PARTICIPATE IN THE TRANSACTION ON A PROPRIETARY BASIS.
SOLELY FOR THE PURPOSES OF THE PRODUCT GOVERNANCE REQUIREMENTS CONTAINED WITHIN: (A) EU DIRECTIVE 2014/65/EU ON MARKETS IN FINANCIAL INSTRUMENTS, AS AMENDED ("MIFID II"); (B) ARTICLES 9 AND 10 OF COMMISSION DELEGATED DIRECTIVE (EU) 2017/593 SUPPLEMENTING MIFID II; AND (C) LOCAL IMPLEMENTING MEASURES (TOGETHER, THE "MIFID II PRODUCT GOVERNANCE REQUIREMENTS"), AND DISCLAIMING ALL AND ANY LIABILITY, WHETHER ARISING IN TORT, CONTRACT OR OTHERWISE, WHICH ANY "MANUFACTURER" (FOR THE PURPOSES OF THE MIFID II PRODUCT GOVERNANCE REQUIREMENTS) MAY OTHERWISE HAVE WITH RESPECT THERETO, THE NEW SHARES IN THE PLACING (THE "ISSUE SHARES") HAVE BEEN SUBJECT TO A PRODUCT APPROVAL PROCESS, WHICH HAS DETERMINED THAT THE ISSUE SHARES ARE: (I) COMPATIBLE WITH AN END TARGET MARKET OF RETAIL INVESTORS AND INVESTORS WHO MEET THE CRITERIA OF PROFESSIONAL CLIENTS AND ELIGIBLE COUNTERPARTIES, EACH AS DEFINED IN MIFID II; AND (II) ELIGIBLE FOR DISTRIBUTION THROUGH ALL DISTRIBUTION CHANNELS AS ARE PERMITTED BY MIFID II (THE "TARGET MARKET ASSESSMENT"). NOTWITHSTANDING THE TARGET MARKET ASSESSMENT, DISTRIBUTORS SHOULD NOTE THAT: THE PRICE OF THE ISSUE SHARES MAY DECLINE AND INVESTORS COULD LOSE ALL OR PART OF THEIR INVESTMENT; THE ISSUE SHARES OFFER NO GUARANTEED INCOME AND NO CAPITAL PROTECTION; AND AN INVESTMENT IN THE ISSUE SHARES IS COMPATIBLE ONLY WITH INVESTORS WHO DO NOT NEED A GUARANTEED INCOME OR CAPITAL PROTECTION, WHO (EITHER ALONE OR IN CONJUNCTION WITH AN APPROPRIATE FINANCIAL OR OTHER ADVISER) ARE CAPABLE OF EVALUATING THE MERITS AND RISKS OF SUCH AN INVESTMENT AND WHO HAVE SUFFICIENT RESOURCES TO BE ABLE TO BEAR ANY LOSSES THAT MAY RESULT THEREFROM. THE TARGET MARKET ASSESSMENT IS WITHOUT PREJUDICE TO THE REQUIREMENTS OF ANY CONTRACTUAL, LEGAL OR REGULATORY SELLING RESTRICTIONS IN RELATION TO THE PLACING. FURTHERMORE, IT IS NOTED THAT, NOTWITHSTANDING THE TARGET MARKET ASSESSMENT, MORGAN STANLEY & CO. INTERNATIONAL PLC, VAN LANSCHOT KEMPEN WEALTH MANAGEMENT NV OR ZONDA PARTNERS AB WILL ONLY PROCURE INVESTORS WHO MEET THE CRITERIA OF PROFESSIONAL CLIENTS AND ELIGIBLE COUNTERPARTIES. 
FOR THE AVOIDANCE OF DOUBT, THE TARGET MARKET ASSESSMENT DOES NOT CONSTITUTE: (A) AN ASSESSMENT OF SUITABILITY OR APPROPRIATENESS FOR THE PURPOSES OF MIFID II; OR (B) A RECOMMENDATION TO ANY INVESTOR OR GROUP OF INVESTORS TO INVEST IN, OR PURCHASE, OR TAKE ANY OTHER ACTION WHATSOEVER WITH RESPECT TO THE ISSUE SHARES. 
EACH DISTRIBUTOR IS RESPONSIBLE FOR UNDERTAKING ITS OWN TARGET MARKET ASSESSMENT IN RESPECT OF THE ISSUE SHARES AND DETERMINING APPROPRIATE DISTRIBUTION CHANNELS.
THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS THAT REFLECT THE COMPANY'S INTENTIONS, BELIEFS, OR CURRENT EXPECTATIONS ABOUT AND TARGETS FOR THE COMPANY'S FUTURE RESULTS OF OPERATIONS, FINANCIAL CONDITION, LIQUIDITY, PERFORMANCE, PROSPECTS, ANTICIPATED GROWTH, STRATEGIES AND OPPORTUNITIES AND THE MARKETS IN WHICH THE COMPANY OPERATES. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ARE NOT HISTORICAL FACTS AND MAY BE IDENTIFIED BY WORDS SUCH AS "BELIEVE", "EXPECT", "ANTICIPATE", "INTEND", "MAY", "PLAN", "ESTIMATE", "WILL", "SHOULD", "COULD", "AIM" OR "MIGHT", OR, IN EACH CASE, THEIR NEGATIVE, OR SIMILAR EXPRESSIONS. THE FORWARD-LOOKING STATEMENTS IN THIS PRESS RELEASE ARE BASED UPON VARIOUS ASSUMPTIONS, MANY OF WHICH ARE BASED, IN TURN, UPON FURTHER ASSUMPTIONS. ALTHOUGH THE COMPANY BELIEVES THAT THE EXPECTATIONS REFLECTED IN THESE FORWARD-LOOKING STATEMENTS ARE REASONABLE, IT CAN GIVE NO ASSURANCES THAT THEY WILL MATERIALIZE OR PROVE TO BE CORRECT. BECAUSE THESE STATEMENTS ARE BASED ON ASSUMPTIONS OR ESTIMATES AND ARE SUBJECT TO RISKS AND UNCERTAINTIES, THE ACTUAL RESULTS OR OUTCOME COULD DIFFER MATERIALLY FROM THOSE SET OUT IN THE FORWARD-LOOKING STATEMENTS AS A RESULT OF MANY FACTORS. SUCH RISKS, UNCERTAINTIES, CONTINGENCIES AND OTHER IMPORTANT FACTORS COULD CAUSE ACTUAL EVENTS TO DIFFER MATERIALLY FROM THE EXPECTATIONS EXPRESSED OR IMPLIED IN THIS RELEASE BY SUCH FORWARD-LOOKING STATEMENTS. THE COMPANY DOES NOT GUARANTEE THAT THE ASSUMPTIONS UNDERLYING THE FORWARD-LOOKING STATEMENTS IN THIS PRESS RELEASE ARE FREE FROM ERRORS NOR DOES IT ACCEPT ANY RESPONSIBILITY FOR THE FUTURE ACCURACY OF THE OPINIONS EXPRESSED IN THIS PRESS RELEASE OR ANY OBLIGATION TO UPDATE OR REVISE THE STATEMENTS IN THIS PRESS RELEASE TO REFLECT SUBSEQUENT EVENTS. UNDUE RELIANCE SHOULD NOT BE PLACED ON THE FORWARD-LOOKING STATEMENTS IN THIS PRESS RELEASE. THE INFORMATION, OPINIONS AND FORWARD-LOOKING STATEMENTS CONTAINED IN THIS PRESS RELEASE SPEAK ONLY AS AT ITS DATE AND ARE SUBJECT TO CHANGE WITHOUT NOTICE. NEITHER THE COMPANY NOR ANYONE ELSE UNDERTAKE ANY OBLIGATION TO REVIEW, UPDATE, CONFIRM OR TO RELEASE PUBLICLY ANY REVISIONS TO ANY FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS THAT OCCUR OR CIRCUMSTANCES THAT ARISE IN RELATION TO THE CONTENT OF THIS PRESS RELEASE.